TMPRSS2 and prostate carcinoma: Though it is present in about 50% of prostate cancer, TMPRSS2-ERG fusion has not been consistently associated with clinical outcomes [16], while the loss of PTEN tumor suppressor gene was found to be of clinical prognostic value [17].